Abstract: The present invention relates to methods for labeling intracellular and extracellular targets of leukocytes, as well as to kits for performing said methods.

Abstract: The present invention relates to methods for labeling intracellular and extracellular targets of leukocytes, as well as to kits for performing said methods.

Abstract: Systems and methods are provided for determining the age of cellular hemoglobin in individual red blood cells in a blood sample by determining the percentage of HbA1c. In embodiments, a method includes measuring side scatter and fluorescence of the individual red blood cells and identifying immature red blood cells and mature red blood cells from the side scatter and fluorescence measurement. In embodiments, data collected includes the exact number of red blood cells, the fraction limits in fluorescence and side scatter units, the mean value of each fraction in fluorescence and side scatter units, the mean FL1 values per fraction in arbitrary units and the mean side scatter values per fraction in arbitrary units. In embodiments, a method also includes deriving a HbA1c content from the measured mean fluorescence of the individual red blood cells and determining the percentage of HbA1c from the HbA1c content and the hemoglobin content of the red blood cells.

Abstract: Systems and methods are provided for determining the age of cellular hemoglobin in individual red blood cells in a blood sample by determining the percentage of HbA1c. In embodiments, a method includes measuring side scatter and fluorescence of the individual red blood cells and identifying immature red blood cells and mature red blood cells from the side scatter and fluorescence measurement. In embodiments, data collected includes the exact number of red blood cells, the fraction limits in fluorescence and side scatter units, the mean value of each fraction in fluorescence and side scatter units, the mean FL1 values per fraction in arbitrary units and the mean side scatter values per fraction in arbitrary units. In embodiments, a method also includes deriving a HbA1c content from the measured mean fluorescence of the individual red blood cells and determining the percentage of HbA1c from the HbA1c content and the hemoglobin content of the red blood cells.

Abstract: The present invention relates to a cell treatment composition for the permeabilization of fixed blood cells, to the use of said composition, to a method for the treatment of a biological sample comprising fixation of said sample and subsequently contacting said biological sample with said cell treatment composition. The invention further relates and to a kit comprising said cell treatment composition.

Abstract: The present invention relates to a cell treatment composition for the permeabilization of fixed blood cells, to the use of said composition, to a method for the treatment of a biological sample comprising fixation of said sample and subsequently contacting said biological sample with said cell treatment composition. The invention further relates and to a kit comprising said cell treatment composition.

Abstract: The present invention relates to methods for labeling intracellular and extracellular targets of leukocytes, as well as to kits for performing said methods.

Abstract: The present invention relates to methods for labeling intracellular and extracellular targets of leukocytes, as well as to kits for performing said methods.

Abstract: The present invention relates to methods for labeling intracellular and extracellular targets of leukocytes, as well as to kits for performing said methods.

Abstract: The present invention relates to a cell treatment composition for the permeabilization of fixed blood cells, to the use of said composition, to a method for the treatment of a biological sample comprising fixation of said sample and subsequently contacting said biological sample with said cell treatment composition. The invention further relates and to a kit comprising said cell treatment composition.

Abstract: A reference control for cell by cell analysis on flow cytometric analyzers contains cellular analogs made of permeated blood cells containing therein aggregated intracellular proteins and preserved antigenic sites thereof, having cellular membrane permeable to antibodies and a suspension medium. The reference control is frozen after being prepared and thawed prior to use. The cellular analogs further contain a fluorescence marker therein. Further disclosed are a method of making the reference control and a method using the reference control, as an internal or stand-alone control, for measurements of cellular hemoglobin and cellular hemoglobin variant of a blood sample.

Abstract: A cell permeabilization and stabilization reagent and method of use are disclosed. The reagent contains a N-acyl sarcosine or a salt thereof, a pH adjusting agent to adjust pH of the reagent in a range from about 4 to about 6; and an aqueous medium; the reagent having a low ionic strength defined by a conductivity of less than 9.0 mS/cm. The reagent further contains bovine serum albumin and glycerol. The reagent may further include an alkyl sulfate surfactant. Upon incubating the cells with the reagent, the reagent permeates the cellular membrane to allow penetration of an intracellular marker, causes intracellular protein aggregation within the cellular membrane, while preserves a cellular constituent for binding with a cellular marker for subsequent analysis by flow cytometry.

Abstract: A reference control for cell by cell analysis on flow cytometric analyzers contains cellular analogs made of permeated blood cells containing therein aggregated intracellular proteins and preserved antigenic sites thereof, having cellular membrane permeable to antibodies and a suspension medium. The reference control is frozen after being prepared and thawed prior to use. The cellular analogs further contain a fluorescence marker therein. Further disclosed are a method of making the reference control and a method using the reference control, as an internal or stand-alone control, for measurements of cellular hemoglobin and cellular hemoglobin variant of a blood sample.

Abstract: A method of measuring cellular hemoglobin of a blood sample includes mixing a blood sample with a permeation reagent, and incubating the sample mixture to permeate cellular membrane of red blood cells and to cause hemoglobin aggregation within the cells; adding a neutralization reagent to inhibit further reactions of the permeation reagent; performing a cell-by-cell measurement of side scatter signals of the red blood cells in the sample mixture on a flow cytometer; and obtaining cellular hemoglobin (Hgbcell) of each red blood cell using the obtained side scatter signals. The method further includes measuring cellular hemoglobin of reticulocytes (Hgbretic) by differentiating reticulocytes using a simultaneous fluorescence measurement. The method also includes measuring cellular percentage of a hemoglobin variant in mature red blood cells or reticulocytes by adding a fluorescent antibody in the neutralization reagent and detecting fluorescence signals of antibody bound hemoglobin variant.

Abstract: A method of measuring cellular hemoglobin of a blood sample includes mixing a blood sample with a permeation reagent, and incubating the sample mixture to permeate cellular membrane of red blood cells and to cause hemoglobin aggregation within the cells; adding a neutralization reagent to inhibit further reactions of the permeation reagent; performing a cell-by-cell measurement of side scatter signals of the red blood cells in the sample mixture on a flow cytometer; and obtaining cellular hemoglobin (Hgbcell) of each red blood cell using the obtained side scatter signals. The method further includes measuring cellular hemoglobin of reticulocytes (Hgbretic) by differentiating reticulocytes using a simultaneous fluorescence measurement. The method also includes measuring cellular percentage of a hemoglobin variant in mature red blood cells or reticulocytes by adding a fluorescent antibody in the neutralization reagent and detecting fluorescence signals of antibody bound hemoglobin variant.

Abstract: A method of measuring micronucleated erythrocyte populations is disclosed. The method includes contacting a sample containing erythrocyte populations with a fluorescently labeled antibody specific to immature erythrocytes among erythrocyte populations; adding an aqueous permeation reagent to the sample and incubating the formed permeation sample mixture for an incubation time sufficient to allow the permeation reagent to render cellular membrane of the erythrocyte populations permeable to RNase and dye; adding a RNase reagent to degrade RNA and to inhibit further reaction of permeation reagent; adding a fluorescent nucleic acid dye reagent to stain DNA representing micronuclei in the erythrocyte populations; performing light scatter and fluorescence measurements of the final sample mixture on a flow cytometer; differentiating micronucleated erythrocyte populations from other cell types; and reporting the micronucleated erythrocyte populations of the sample.

Abstract: A method of measuring cellular hemoglobin of a blood sample includes mixing a blood sample with a permeation reagent, and incubating the sample mixture to permeate cellular membrane of red blood cells and to cause hemoglobin aggregation within the cells; adding a neutralization reagent to inhibit further reactions of the permeation reagent; performing a cell-by-cell measurement of side scatter signals of the red blood cells in the sample mixture on a flow cytometer; and obtaining cellular hemoglobin (Hgbcell) of each red blood cell using the obtained side scatter signals. The method further includes measuring cellular hemoglobin of reticulocytes (Hgbretic) by differentiating reticulocytes using a simultaneous fluorescence measurement. The method also includes measuring cellular percentage of a hemoglobin variant in mature red blood cells or reticulocytes by adding a fluorescent antibody in the neutralization reagent and detecting fluorescence signals of antibody bound hemoglobin variant.

Abstract: A cell permeabilization and stabilization reagent and method of use are disclosed. The reagent contains a N-acyl sarcosine or a salt thereof, a pH adjusting agent to adjust pH of the reagent in a range from about 4 to about 6; and an aqueous medium; the reagent having a low ionic strength defined by a conductivity of less than 9.0 mS/cm. The reagent further contains bovine serum albumin and glycerol. The reagent may further include an alkyl sulfate surfactant. Upon incubating the cells with the reagent, the reagent permeates the cellular membrane to allow penetration of an intracellular marker, causes intracellular protein aggregation within the cellular membrane, while preserves a cellular constituent for binding with a cellular marker for subsequent analysis by flow cytometry.

Abstract: The present invention relates to an antibody for the detection quantification, or isolation of basophils, mast cells, the precursor cells of basophils or mast cells, or a surface structure of basophils or mast cells. This antibody corresponds to an antibody with the designation 97A6, produced and released by hybridoma cells that were deposited in accordance with the Budapest Treaty on Feb. 12, 1997 under accession number DSM ACC 2297 at Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ).

Abstract: A reference control for cell by cell analysis on flow cytometric analyzers contains cellular analogs made of permeated blood cells containing therein aggregated intracellular proteins and preserved antigenic sites thereof, having cellular membrane permeable to antibodies and a suspension medium. The reference control is frozen after being prepared and thawed prior to use. The cellular analogs further contain a fluorescence marker therein. Further disclosed are a method of making the reference control and a method using the reference control, as an internal or stand-alone control, for measurements of cellular hemoglobin and cellular hemoglobin variant of a blood sample.